Biologics development is a complex and expensive process. Active pharmaceutical ingredients (API) for biologics manufacturing services have become a fast-growing sector in the pharmaceutical industry due to the adoption of advanced technologies for its production, the inclination of pharma companies towards outsourcing their activities, emerging monoclonal antibodies applications, as well as the development of advanced antibody therapies.
The increasing number of approvals of biologics over the years has increased the volume of contracts for innovator APIs and biologic-dose outsourcing.
Find the leading API biologics companies in contract marketing
Pharmaceutical Technology has listed some of the top API biologics companies in contract marketing based on our intel, insights and decades-long experience in the sector. The list includes providers of development services, biologics management supply chain solutions, clinical trial services, commercial and logistics services, as well as packaging, labelling and distributing services for biologics.
These companies offer support for manufacturing large-molecule biologics from development to commercial scale, including cell culture development and optimisation, upstream and downstream development process and optimisation, as well as drug formulation, fermentation, biotransformation, cell line development, equipment, technologies and processes and several other solutions and products.
The information contained within the download document is designed for pharmaceutical executives, developers, research scientists and associates, regulatory solutions consultants, and any other individual involved in API biologics production in the pharmaceutical industry.
The download contains detailed information on the providers and their services and solutions, alongside contact details to aid your purchasing or hiring decision.
What is driving the biologics API manufacturing services industry
The expiration of several biological patents and rising investments in orphan drugs over the years have boosted the growth of the biologics API manufacturing services industry. Emerging economies are offering attractive opportunities to the industry to grow, with more small and emerging companies looking to outsource biologics development on a contract basis.
The use of single-use bioprocessing technology in the pharma industry effectively helps in cost reduction, increasing productivity, saving energy, water and time, as well as easier disposal. The technology is also expected to be a vital driver of the biologics API manufacturing services industry over the years.